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ABSTRACT 
Background: Prescription medication copayments can be a financial burden to many patients. When patients cannot afford their 
medications, they may become nonadherent, and as a result, this can lead to an increase in chronic disease complications and healthcare 
costs. Objective: The objective of this study was to determine if zero copayments have an effect on medication adherence in a community 
pharmacy. Methods: This retrospective cohort study examined the prescription refill records of patients who filled specific generic 
medications for hypertension, hyperlipidemia, and gastroesophageal reflux disease (GERD) in 2016 at the NSU Clinic Pharmacy. The 
adherence rates of patients with zero copayments were compared to the adherence rates of patients with copayments greater than $0. 
Adherence was determined by calculating the proportion of days covered (PDC). Patients were considered adherent if their PDC was greater 
than or equal to 80%. Results: GERD patients with no copayments had average PDC ratios of 87.4% and were statistically significantly 
more adherent than GERD patients with copayments, who had average PDC ratios of 76.7% (P = 0.042). Hyperlipidemia and hypertension 
patients with no copayments had average PDC ratios of 89.3% and 90.3%, respectively, and those with copayments had PDC ratios of 
85.3% (P = 0.314) and 87.9% (P = 0.534). Conclusion: Overall, patients with $0 copayments had higher adherence rates than patients with 
copayments greater than $0. GERD patients with no copayments were significantly more adherent than GERD patients with copayments. 
However, no statistically significant difference was found between patients with or without copayments in the hyperlipidemia and 
hypertension cohorts. Further studies are recommended to analyze additional factors that may influence medication adherence. 
 
 
 
INTRODUCTION 
Prescription medication nonadherence is a major health problem 
in the United States. Previous research studies have shown that 
medication nonadherence leads to poor health outcomes and 
chronic disease state complications, resulting in increased 
utilization of physician office visits, urgent care and emergency 
room services, and hospitalizations, as well as increased 
morbidity and mortality.1-5 It is estimated that medication 
nonadherence in the United States is responsible for about 10% 
of hospitalizations and at least 125,000 deaths annually.5 As a 
result, medication nonadherence leads to an overall increase in 
healthcare expenditures, costing the healthcare system between 
$100 billion to $289 billion per year.2-3,5 
 
Medication nonadherence can be attributed to multiple causes, 
such as patient sociodemographic characteristics, economic 
factors, patient beliefs and perceptions, cognitive function, 
medication adverse effects, disease severity, medication regimen 
complexity, treatment duration, access to care,  
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prescription drug coverage, etc.3,5-6 Medication cost is considered 
one of the most significant barriers to adherence for many 
patients. Several studies suggest that an inverse relationship exists 
between prescription drug copayments and medication 
adherence.1-3,7-10 When patients cannot afford to purchase their 
medications, they may become nonadherent to their medication 
regimens by skipping doses, splitting tablets, or stopping their 
medications altogether. This can lead to poor health outcomes and 
increased healthcare costs.1-2,7,8,10 
 
Hypertension and hyperlipidemia are among two of the most 
common chronic medical conditions for which prescriptions are 
filled in community pharmacies in the United States. Adherence 
to antihypertensive and antihyperlipidemic medications is critical 
to the management of these mostly asymptomatic conditions in 
order to prevent and reduce the risk of future cardiovascular 
events.11-14 Uncontrolled hypertension can lead to serious 
cardiovascular complications, such as stroke, heart failure, atrial 
fibrillation, coronary artery disease, and peripheral vascular 
disease.11 Likewise, uncontrolled hypercholesterolemia can 
increase the risk of coronary and cerebrovascular events. 
Complications from uncontrolled hypertension and 
hyperlipidemia can ultimately increase the risk of cardiovascular-
related morbidity and mortality.13,15 For example, poor statin use 
and uncontrolled hypercholesterolemia alone is responsible for 
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nearly 635,000 new coronary events, almost 800,000 strokes, and 
about one in six deaths annually.15  
 
Gastroesophageal reflux disease (GERD) is another health 
condition frequently seen in community pharmacies. GERD is 
mostly a symptomatic condition in which patients usually 
experience heartburn and acid reflux. Adherence to acid-
reducing medications is important in the treatment of GERD. 
However, studies show that treatment failure is high among 
GERD patients due to medication nonadherence.6,16 Uncontrolled 
GERD can lead to complications such as esophagitis, esophageal 
erosions, Barrett’s esophagus, and esophageal 
adenocarcinoma.6,16-17 GERD is the most expensive 
gastrointestinal disease in the U.S. and is associated with over 
$10 billion in direct medical and drug costs.17 
 
Prior research studies suggest that medication adherence can be 
improved by reducing patient copayments and out-of-pocket 
costs.1,3,5,18-19 However, there is a limited amount of published 
research available regarding whether $0 copayments have an 
impact on medication adherence, particularly in patients with 
commercial insurance. The objective of this study was to 
determine if zero copayments had an effect on medication 
adherence on prescriptions filled in a community pharmacy 
setting. 
 
METHODS 
Data Source and Study Design 
This retrospective cohort study was approved by the Institutional 
Review Board at Nova Southeastern University. The study was 
conducted at the university’s full-service community pharmacy 
on campus in Fort Lauderdale, Florida. The pharmacy’s 
prescription refill records were used to determine the medication 
adherence rates of patients who filled specific generic 
medications for hypertension, hyperlipidemia, and GERD. 
 
Subjects 
Adult patients aged ≥ 18 years who filled at least two 
prescriptions between January 1st, 2016 through December 31st, 
2016 for any of the following disease states and medications 
were included in the study: hypertension (lisinopril, losartan), 
hyperlipidemia (atorvastatin, simvastatin), and GERD 
(omeprazole, pantoprazole). Patients less than 18 years of age 
and patients who became deceased in 2016 during the study 
period were excluded from the study. For each disease state, 
patients were categorized into either the treatment group or the 
control group based on their copayments. The treatment group 
consisted of patients with zero copayments for their medications, 
and the control group included patients with copayments greater 
than $0 for their medications. All patients included in the study 
had commercial insurance plans. 
 
Patient Demographics and Baseline Characteristics 
Patient demographics and baseline characteristics were 
compared between zero-copayment and copayment groups for 
each disease state. The variables analyzed included age, gender, 
number of concurrent medications, and whether patients were 
new or continuous patients to therapy. Patients were classified as 
new patients if they started the study medication during any 
month in 2016, and patients were considered to be continuous 
patients if they started the study medication any time before 
2016. 
 
Adherence 
For each patient, medication adherence was determined by 
calculating the Proportion of Days Covered (PDC). PDC is the 
preferred method of measuring medication adherence for the 
chronic diseases discussed in this research study and is supported 
by the Pharmacy Quality Alliance, the Centers of Medicare and 
Medicaid Services, and the Centers for Disease Control and 
Prevention.20-21 The following formula was used to calculate PDC: 
 
PDC = (Number of Days in Period “Covered” / Number of Days in 
Period) × 100% 
 
The numerator refers to the number of days during the study 
period in which patients had medication based on pharmacy pick 
up dates and days’ supply. Meanwhile, the denominator refers to 
the number of days of the study period for each patient (i.e. 365 
days for continuous patients, and the number of days from the 
index date in which the patient first picked up the medication in 
2016 until the end of the year for new patients). Patients were 
considered to be adherent if their PDC was greater than or equal 
to 80%, and patients were classified as nonadherent if their PDC 
was less than 80%. The PDC threshold of 80% or greater is 
considered to be the goal adherence rate for most chronic 
disease states in which medications are believed to provide the 
most clinical benefit to patients.20-21 
 
Statistical Analyses 
A series of descriptive measures associated with demographic 
and baseline characteristics were provided as counts, percentage 
means, and standard deviations. Chi-square tests were used to 
assess the statistical significance of differences for categorial 
variables. Differences in medication adherence rates between 
zero-copayment and copayment populations were compared 
using t-test. A critical value of 0.05 was set as the threshold for 
statistical significance. 
 
RESULTS 
There was a total of 320 unique patients that met the inclusion 
criteria. One patient was excluded from the study due to death 
during the study period, and one patient was excluded due to 
having an age less than 18 years of age. It is important to note 
that about a third of the patients belonged to more than one 
disease cohort. 
 
As shown on Table 1, the hypertension cohort consisted of 151 
patients, of which 134 patients had no copayments (i.e. the 
treatment group), and 17 patients had copayments greater than 
$0 (i.e. the control group). The mean age for the treatment and 
control groups were 59.21 years and 54.29 years, respectively. 
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The hyperlipidemia cohort consisted of 169 patients, in which 154 
patients had $0 copayments, and 15 patients had copayments 
greater than $0. The mean age for both the treatment and 
control groups were 60.31 and 60.47 years, respectively. 
Meanwhile, the GERD cohort consisted of 104 patients, of which 
87 had no copayments, and 17 patients had copayments greater 
than $0. The treatment group had a mean age of 56.49 years, 
while the control group had a mean age of 49.05 years. 
 
Overall, patients with no copayments had higher adherence rates 
than patients with copayments greater than zero dollars; 
however, no statistically significant differences were found 
between patients with and without copayments for the 
hyperlipidemia and hypertension patients, as illustrated in Table 
2. On the other hand, within the GERD cohort, there was a 
statistically significant difference between the treatment and 
control groups: patients with zero-dollar copayments had an 
average PDC of 87.4%, while patients with copayments greater 
than $0 had an average PDC of 76.7% (P = 0.042). 
 
DISCUSSION 
Our study results showed that the zero-dollar copayment design 
significantly improved the adherence rates of GERD patients. 
Similar results were found in the study conducted by Cohen et. 
al., in which dispensing rates increased as copayments were 
eliminated for some medications, including those for GERD; as 
zero copayments went into effect, prescription filling rates by 
patients increased, thus increasing medication adherence.9 In 
addition, in the literature review conducted by Domingues et. al., 
it was found that patients less than 60 years of age are more likely 
to be less adherent to medications for symptomatic conditions.6 
This observation can be seen in our study, in which GERD patients 
with copayments had an average age less than 60 years and were 
nonadherent to their GERD medications. 
 
Conversely, our study found that a decrease in copayments was 
not associated with an increase in adherence rates in 
hypertension or hyperlipidemia. One of the reasons for the lack of 
statistically significant differences within the hypertension and 
hyperlipidemia cohorts might be the fact that most copayment 
patients had very small copayment amounts, as shown in Table 2 
and Figure 1. It was found that 65.6% of hypertensive and 
hyperlipidemic patients (i.e. 21 patients) in the treatment groups 
had copayments of $5.00 or less, 21.9% (i.e. seven patients) had 
copayments between $5.01 and $10.00, and only 9.4% (i.e. four 
patients) had copayments between $10.01 and $20.00. None of 
the patients had copayments ≥ $20. Because most copayments 
were minimal, prescription costs may not have been a barrier to 
medication adherence for patients in the hypertension and 
hyperlipidemia cohorts. 
 
Another possible explanation why copayments may not have 
significantly impacted the adherence rates of hypertension and 
hyperlipidemia patients might be due to disease severity, 
comorbidities, and patient knowledge and awareness of the 
consequences of nonadherence to cardiovascular medications. 
The studies conducted by Schneeweiss et. al. and Wang et. al. 
found that increased copayments, coinsurance, and patient out-
of-pocket costs decreased adherence; however, the adherence 
rates of post-myocardial infarction patients and patients with 
higher cardiovascular comorbidities were not affected by 
increased medication costs. The authors of both studies mention 
that the patients may have been more aware of the importance 
of medication adherence to prevent future adverse 
cardiovascular events such as myocardial infarction, stroke, and 
death.10,14 It is unknown whether the patients in our study 
experienced high cardiovascular disease severity and 
comorbidities; however, since the pharmacy is located within an 
academic institution of higher learning, many of the patients 
included in our study might have a better understanding of the 
importance of taking their medications as prescribed to prevent 
serious cardiovascular events in the future. 
 
Wang et. al. suggested that the lack of over-the-counter (OTC) 
alternatives for hypertension and hyperlipidemia could play a 
role in influencing medication adherence rates for cardiovascular 
patients.10 The medications typically prescribed for hypertension 
and hyperlipidemia, including the ones analyzed in this study, are 
available only by prescription in the United States, and patients 
have no OTC alternatives to treat their condition; therefore, 
patients with hypertension and hyperlipidemia are more likely to 
fill their prescription medications.10 In contrast, a number of 
proton pump inhibitors, including omeprazole, are available 
over-the-counter for GERD. It is possible that some of the 
patients in our study could have been taking OTC proton pump 
inhibitors or other OTC GERD medications such as histamine H2-
receptor antagonists (ex. ranitidine); as a result, they may not 
have refilled their prescription GERD medications, thus affecting 
our study’s adherence results for the GERD patients. 
 
Limitations 
Since our study utilized prescription refill records at a single 
pharmacy, it is not known whether patients utilized another 
pharmacy for any of their refills for their medications. Also, as 
mentioned above, it is possible that some GERD patients may 
have used OTC proton pump inhibitors or other GERD medication 
alternatives, which is information that is unobtainable from 
pharmacy refill records. In addition, per the literature, 
prescription refill records may not be an accurate measure to 
assess true medication adherence because refill and pick up 
records assume that patients are taking their medications. 
However, it is impossible to know whether patients are truly 
taking their medications as prescribed without direct 
observation. 
  
CONCLUSION AND FUTURE IMPLEMENTATIONS 
Although the sample sizes of our study population were rather 
small, we can nevertheless conclude that the presence of a zero-
dollar copayment structure increased adherence rates for 
patients with the symptomatic condition of GERD, as there was a 
statistically significant difference in the PDC rates between the 
treatment group and the control group. Based on our results, we 
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can recommend that prescription benefit plans and health 
insurers consider removing copayments for symptomatic 
conditions such as GERD. Albeit it may cost insurance payers 
more money upfront, such a policy has the potential to save 
much more money in the long run because it can lead to 
increased medication adherence, which can result in fewer 
hospitalizations and other costly healthcare interventions. 
 
Additional studies are recommended to analyze other 
contributing factors that might affect adherence, such as 
geographic location, socioeconomic status, education, health 
literacy, race, ethnicity, language, etc. Also, it would be 
reasonable to evaluate the impact that pharmacists can have in 
affecting medication adherence rates. Previous studies have 
shown that pharmacists play an important role in increasing 
adherence rates through medication therapy management, 
patient counseling, and education.3-5,22-23 
 
When it comes to prescription medication costs, third-party 
insurance payers can influence medication adherence when these 
entities establish their drug formularies and copayment tier 
structures. Previous studies have shown that medication costs 
affect adherence rates. By decreasing patient prescription 
copayments and medication out-of-pocket costs, third-party 
insurance payers can help increase medication adherence and 
improve health outcomes, which may result in decreased health 
complications, hospitalizations, morbidity, and mortality, and lead 
to an overall decrease in healthcare costs and an increase in 
savings in the long run.1-2,5,7-8,10,14,17-19 
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Table 1. Patient Demographics 
 
GERD = Gastroesophageal Reflux Disease 
  
 Hypertension 
N = 151 
Hyperlipidemia 
N = 169 
GERD 
N = 104 
Baseline    
Characteristic 
Treatment 
Group 
n = 134 
Control 
Group 
n = 17 
Treatment 
Group                                 
n = 154 
Control 
Group                                   
n = 15 
Treatment 
Group                         
n = 87 
Control 
Group                          
n = 17 
 Mean Age, 
     n (Range) 59.21 (26 – 91) 54.29 (26 – 94) 60.31 (25 – 88) 60.47 (24 – 85) 56.49 (18 – 84) 49.06 (18 – 79) 
 Gender      
     Female, n (%) 60 (44.78) 10 (58.82) 70 (45.45) 8 (53.33) 50 (57.47) 10 (58.82) 
     Male, n (%) 74 (55.22) 7 (41.18) 84 (54.54) 7 (46.67) 37 (42.53) 7 (41.18) 
 Concurrent   
 Medications 
 
     
     < 5, n (%) 89 (66.42) 10 (58.82) 103 (66.88) 9 (60) 53 (60.92) 11 (64.71) 
     ≥ 5, n (%) 45 (33.58) 7 (41.18) 51 (33.12) 6 (40) 34 (39.08) 6 (35.29) 
 New Patients,      
     n (%) 29 (21.64) 8 (47.06) 23 (14.94) 5 (33.33) 27 (31.03) 8 (47.06) 
 Continuous   
 Patients, n (%) 105 (78.36) 9 (52.94) 131 (85.06) 10 (66.67) 60 (68.97) 9 (52.94) 
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Table 2. Adherence Rates by Proportion of Days Covered (PDC) 
 
Disease Group Average Copayment N Average PDC 
Standard 
Deviation P Value 
Hypertension 
Treatment $0.00 134 90.34% 14.81 
0.534 
Control $3.63 17 87.90% 18.25 
Hyperlipidemia 
Treatment $0.00 154 89.34% 14.39 
0.314 
Control $6.75 15 85.33% 17.60 
GERD 
Treatment $0.00 87 87.37% 14.80967 
0.042* 
Control $5.19 17 76.66% 18.25181 
GERD = Gastroesophageal Reflux Disease; PDC = Proportion of Days Covered. 
* Indicates statistically significant (P < 0.05) 
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Figure 1. Number of Patients with Copayments 
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